Shisi Pharmaceutical Group (02005) has obtained the drug production registration approval for latemovir injection (12ml: 240mg) from the China National Drug Administration

Zhitongcaijing · 3d ago

Zhitong Finance App News, Shisi Pharmaceutical Group (02005) issued an announcement. The Group has obtained approval from the China National Drug Administration for drug production registration for letmovir injection (12ml: 240mg), which is a Class 4 chemical drug, and is deemed to have passed the consistency evaluation.

Letmovir injection is mainly used for cytomegalovirus (CMV) seropositive adult recipients receiving allogeneic hematopoietic stem cell transplantation to prevent cytomegalovirus infection and cytomegalovirus disease. Letmovir injections should be used in conjunction with basic infusions and should be used during the perioperative period of hematopoietic stem cell transplantation. Relying on the existing advantages of basic infusions, the Group continues to improve the therapeutic injection product pipeline. This approval further enriches the Group's perioperative product portfolio.